NCT04302025 2026-04-03A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Genentech, Inc.Phase 2 Recruiting99 enrolled
NCT04835805 2026-03-30A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Genentech, Inc.Phase 1 Active not recruiting65 enrolled